

# Neal Hermanowicz

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4120445/publications.pdf>

Version: 2024-02-01

17  
papers

733  
citations

1039406

9  
h-index

940134

16  
g-index

17  
all docs

17  
docs citations

17  
times ranked

929  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 543.	4.5	312
2	The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 625-633.	1.4	168
3	&lt;p&gt;Impact of non-motor symptoms in Parkinson's disease: a PMDAAlliance survey&lt;/p&gt;. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 2205-2212.	1.0	55
4	Treatment of Oromandibular Dystonia With Botulinum Toxin. <i>Laryngoscope</i> , 1991, 101, 1216-1218.	1.1	42
5	PKG Movement Recording System Use Shows Promise in Routine Clinical Care of Patients With Parkinson's Disease. <i>Frontiers in Neurology</i> , 2019, 10, 1027.	1.1	38
6	Frameless Stereotactic Robot-Assisted Subthalamic Nucleus Deep Brain Stimulation: Case Report. <i>World Neurosurgery</i> , 2017, 97, 762.e11-762.e14.	0.7	35
7	Fosmetpantotenate Randomized Controlled Trial in Pantothenate Kinase-Associated Neurodegeneration. <i>Movement Disorders</i> , 2021, 36, 1342-1352.	2.2	20
8	Drug Therapy for Parkinson's Disease. <i>Seminars in Neurology</i> , 2007, 27, 97-105.	0.5	11
9	&lt;p&gt;Patient and physician perceptions of disease management in Parkinson's disease: results from a US-based multicenter survey&lt;/p&gt;. <i>Neuropsychiatric Disease and Treatment</i> , 2019, Volume 15, 1487-1495.	1.0	10
10	Two-year clinical outcomes associated with robotic-assisted subthalamic lead implantation in patients with Parkinson's disease. <i>Journal of Robotic Surgery</i> , 2020, 14, 559-565.	1.0	10
11	Impact of Isolation During the COVID-19 Pandemic on the Patient Burden of Parkinson's Disease: A PMDAAlliance Survey. <i>Neuropsychiatric Disease and Treatment</i> , 2022, Volume 18, 633-643.	1.0	9
12	Management of Parkinson's disease. <i>Postgraduate Medicine</i> , 2001, 110, 15-28.	0.9	6
13	The Effect of Gabapentin Enacarbil on Pain Associated with Moderate-to-Severe Primary Restless Legs Syndrome in Adults: Pooled Analyses from Three Randomized Controlled Trials. <i>CNS Drugs</i> , 2016, 30, 443-454.	2.7	5
14	Delusional misidentification in Parkinson's disease: report of two cases and a review. <i>Postgraduate Medicine</i> , 2018, 130, 280-283.	0.9	5
15	Changing the treatment paradigm for Parkinson's disease psychosis with pimavanserin. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 681-691.	1.3	5
16	The Emerging Role of Pimavanserin in the Management of Parkinson's Disease Psychosis. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2017, 23, S2-S8.	0.5	2
17	Neurological commentary addressing the article titled "Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus". <i>CNS Spectrums</i> , 2018, 23, 352-354.	0.7	0